Proteases in cutaneous melanoma

Annals of Medicine

Volumn 30, Issue 5, 1998, Pages 431-442

  Ferrier, Cilia M ^a   Van Muijen, Goos N P ^a   Ruiter, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Invasion; Melanoma; Proteases

Indexed keywords

PROTEINASE;

ANIMAL MODEL; CELL DAMAGE; HUMAN; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TUMOR; TUMOR GROWTH;

EID: 0031726982     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809002484     Document Type: Review

References (86)

1. Clark WH, Elder DE, Guerry D, Epstein MN, Greene MH, van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-65.
2. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of tumor progression in human melanocytes. Lab Invest 1987; 56: 461-74.
3. Albino AP, Reed JA, McNutt NS. Molecular biology of cutaneous malignant melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles & Practice of Oncology. 5th edn. Lippincott-Raven: Philadelphia; 1997: 1935-46.
4. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 4: 93-126.
5. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351-62.
6. Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein 1996; 49: 163-73.
7. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71; 1368-83.
8. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996; 65: 717-22.
9. Dano K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
10. Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191-217.
11. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 50: 273-328.
12. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6: 3-26.
13. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95.
14. Monsky WL, Chen W-T. Proteases and cell adhesion proteins in cancer. Semin Cancer Biol 1993; 4: 251-8.
15. DeClerck YA, Laug WE. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme Protein 1996; 49: 72-84.
16. de Vries TJ, van Muijen GNP, Ruiter DJ. The plasminogen activation system in tumour invasion and metastasis. Pathol Res Pract 1996; 192: 718-33.
17. de Vries TJ, van Muijen GNP, Ruiter DJ. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 1996; 6: 79-88.
18. de Vries TJ, Ruiter DJ, Weidle UH, van Muijen GNP. Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions - a minireview. Fibrinolysis 1996; 10 Suppl 2: 91-4.
19. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613-8.
20. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996; 213: 65-80.
21. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
22. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol 1997; 183: 377-9.
23. 2-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 1996; 56: 1432-9.
24. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-8.
25. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-71.
26. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116-22.
27. 3 in melanoma metastasis. Cancer Metastasis Rev 1995; 14: 241-52.
28. Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995; 95: 2096-103.
29. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-24.
30. 3 Cell 1996; 85: 683-93.
31. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 259-70.
32. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18: 415-7.
33. 2-macroglobulin secretion. Cell Regul 1990; 1: 895-905.
34. Bizik J, Stephens RW, Grófová M, Vaheri A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem 1993; 51: 326-35.
35. Houde M, de Bruyne G, Bracke M, et al. Differential regulation of gelatinase B and tissue-type plasminogen activator expression in human Bowes melanoma cells. Int J Cancer 1993; 53: 395-400.
36. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-71.
37. Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995; 129: 335-44.
38. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
39. Huijzer JC, Uhlenkott CE, Meadows GG. Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion. Int J Cancer 1995; 63: 92-9.
40. Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 246-53.
41. Montgomery AMP, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994; 54: 5467-73.
42. 1 integrins during human melanoma cell invasion. Cancer Res 1993; 53: 3411-5.
43. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-13.
44. Stack MS, Gray RD, Pizzo SV. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res 1993; 53: 1998-2004.
45. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115: 191-9.
46. Meissauer A, Kramer MD, Hofmann M, et al. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp Cell Res 1991; 192: 453-9.
47. Meissauer A, Kramer MD, Schirrmacher V, Brunner G. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res 1992; 199: 179-90.
48. Montgomery AMP, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53: 693-700.
49. Monsky WL, Lin C-Y, Aoyama A, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994; 54: 5702-10.
50. Hendrix MJC, Wood WR, Seftor EA, et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990; 50: 4121-30.
51. Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci U S A 1989; 86: 5424-8.
52. Khokha R, Zimmer MJ, Graham CH, Lala PK, Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992; 84: 1017-22.
53. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995; 14: 908-17.
54. Yu H, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50: 7623-33.
55. Alizadeh H, Ma D, Berman M, et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14: 449-58.
56. Shapiro RL, Duquette JG, Roses DF, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597-604.
57. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-8.
58. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87: 4718-22.
59. Mueller BM, Yu YB, Laug WE. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 1995; 92: 205-9.
60. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8.
61. Gartner MFRM, Fearns C, Wilson EL, Cambell JAH, Dowdle EB. Unusual growth characteristics of human melanoma xenografts in the nude mouse: a model for desmoplasia, dormancy and progression. Br J Cancer 1992; 65: 487-90.
62. Nemeth JA, Goolsby CL. TIMP-2, a growth-stimulatory protein from SV40-transformed human fibroblasts. Exp Cell Res 1993; 207: 376-82.
63. Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992; 296: 231-4.
64. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-7.
65. Ganesh S, Sier CFM, Heerding MM, et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997; 75: 1793-801.
66. Fräki JE, Nieminen S, Hopsu-Havu VK. Proteolytic enzymes and plasminogen activator in melanoma. J Cutan Pathol 1979; 6: 195-200.
67. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C. Plasminogen activators in human malignant melanoma. J Natl Cancer Inst 1984; 72: 1213-22.
68. Kwaan HC, Radosevich JA, Xu CG, Lastre C. Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma. Tumor Biol 1988; 9: 301-6.
69. Delbaldo C, Masouye I, Saurat J-H, Vassalli J-D, Sappino A-P. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994; 54: 4547-52.
70. de Vries TJ, Quax PHA, Denijn M, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
71. Woolley DE, Grafton CA. Collagenase immunolocalization studies of cutaneous secondary melanomas. Br J Cancer 1980; 42: 260-5.
72. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-9.
73. van den Oord JJ, Paemen L, Opdenakker G, De Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-70.
74. Wagner SN, Ruhri C, Kunth K, et al. Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma. Diagn Mol Pathol 1992; 1: 200-5.
75. Podhajcer OL, Bover L, Bravo AI, et al. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 1995; 104: 340-4.
76. Yoshii A, Kageshita T, Tsushima H, Ono T. Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours. Arch Dermatol Res 1995; 287: 209-13.
77. Fröhlich E, Schaumburg-Lever G, Klessen C. Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma. Br J Dermatol 1995; 132: 867-75.
78. Kageshita T, Yoshii A, Kimura T, et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch Dermatol Res 1995; 287: 266-72.
79. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
80. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4.
81. Conway JG, Trexler SJ, Wakefield JA, et al. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 1996; 14: 115-24.
82. Oku T, Ata N, Yonezawa K, et al. Antimetastatic and antitumor effect of a recombinant human tissue inhibitor of metalloproteinases-2 in murine melanoma models. Biol Pharm Bull 1997; 20: 843-9.
83. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-62.
84. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74.
85. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Malignant melanoma. Interaction with coagulation and fibinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
86. Kos J, Štabuc B, Schweiger A, et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 1997; 3: 1815-22.